– USA, MA – Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced the appointment of Dr. Percy Carter (Ph.D.) to its Board of Directors.
“We are thrilled to add Percy to our experienced Board of Directors to help Cellarity’s management team re-write the rules of drug discovery and drive strong value creation in the years to come,” said Board Chairman, Steve Berenson.
About Dr. Percy Carter
Dr. Percy Carter serves as CSO at Blueprint Medicines and formerly held several leadership roles in the biopharma industry, including Global Head of Discovery Sciences at Janssen Pharmaceuticals and SVP and Head of Discovery at Bristol Myers Squibb.
Dr. Carter comes to Cellarity’s Board with a strong track record of shaping and leading drug discovery and platform development. As CSO of Blueprint Medicines, she has advanced a broad research pipeline of innovative therapeutic candidates addressing significant medical needs in allergy/inflammation and oncology/hematology, while leading the expansion of the company’s core scientific platform to encompass targeted protein degradation. During his time at BMS, Dr. Carter led teams that identified and progressed promising drug candidates through discovery into clinical development. His leadership was also instrumental in advancing BMS’s synthetic chemistry and drug discovery strategies, leading to multiple innovations in both discovery platforms and programs.
“I am delighted to join the Board of Directors at Cellarity as the company sets out to challenge the status quo of drug discovery with its unique platform, ultimately bringing value to patients via novel biology and differentiated drug candidates,” said Dr. Carter. “Cellarity’s platform is unique in that it uses advanced computational methods to decode cell behavior, pinpointing novel biological pathways to uncover drug candidates and ultimately develop highly effective therapies.”
About Cellarity
Founded by Flagship Pioneering in 2019, Cellarity is fundamentally redesigning the way drugs are created. By shifting the starting point of drug discovery from a single target to the cellular dysfunction underlying diseases, the company unravels the complexity of biology to create medicines that are out of reach with the traditional approaches. Cellarity has developed a platform that uses proprietary AI models trained on more than 30 million single-cell transcriptomes to discover novel actionable biology and create non-intuitive drug candidates for a vast array of diseases. The company currently has programs ongoing in hematology and immunology, as well as an ongoing collaboration with Novo Nordisk in metabolic dysfunction-associated steatohepatitis.
For more: https://cellarity.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.